Sandbox: sadaf: Difference between revisions

Jump to navigation Jump to search
Ssharfaei (talk | contribs)
Ssharfaei (talk | contribs)
Line 265: Line 265:
! align="center" style="background:#DCDCDC;" + |MYH-9 related disorders
! align="center" style="background:#DCDCDC;" + |MYH-9 related disorders
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 295: Line 295:
! align="center" style="background:#DCDCDC;" + |Bernard-Soulier syndrome
! align="center" style="background:#DCDCDC;" + |Bernard-Soulier syndrome
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 324: Line 324:
|-
|-
! align="center" style="background:#DCDCDC;" + |Gray platelet syndrome
! align="center" style="background:#DCDCDC;" + |Gray platelet syndrome
|
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 348: Line 335:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |Wiskott-Aldrich syndrome
! align="center" style="background:#DCDCDC;" + |Wiskott-Aldrich syndrome
|
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 378: Line 366:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |Thrombocytopenia with absent radius (TAR) syndrome
! align="center" style="background:#DCDCDC;" + |Thrombocytopenia with absent radius (TAR) syndrome
|
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 411: Line 398:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |Alport syndrome
! align="center" style="background:#DCDCDC;" + |Alport syndrome
|
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 438: Line 425:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="left" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |Von Willebrand disease
! align="center" style="background:#DCDCDC;" + |Von Willebrand disease
|
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 475: Line 475:
! align="center" style="background:#DCDCDC;" + |Nutrient deficiencies
! align="center" style="background:#DCDCDC;" + |Nutrient deficiencies
! align="center" style="background:#DCDCDC;" + |Folate, vitamin B12, copper
! align="center" style="background:#DCDCDC;" + |Folate, vitamin B12, copper
|an autoimmune mechanism
| align="center" style="background:#F5F5F5;" + |
!+
| align="center" style="background:#F5F5F5;" + | +
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
!
!
|-
|-
Line 538: Line 539:
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rheumatologic/autoimmune disorders
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rheumatologic/autoimmune disorders
! colspan="2" align="center" style="background:#DCDCDC;" + |Immune thrombocytopenia
! colspan="2" align="center" style="background:#DCDCDC;" + |Immune thrombocytopenia
|Antibody-mediated platelet destruction
| align="center" style="background:#F5F5F5;" + |Antibody-mediated platelet destruction
|
| align="center" style="background:#F5F5F5;" + |
| +
| align="center" style="background:#F5F5F5;" + |+
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |Moderate to severe
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 568: Line 569:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Systemic lupus erythematosus (SLE)
! colspan="2" align="center" style="background:#DCDCDC;" + |Systemic lupus erythematosus (SLE)
|
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 598: Line 599:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Antiphospholipid syndrome (APS)
! colspan="2" align="center" style="background:#DCDCDC;" + |Antiphospholipid syndrome (APS)
|autoantibody-mediated syndrome
| align="center" style="background:#F5F5F5;" + |Autoantibody-mediated syndrome
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Felty's syndrome
! colspan="2" align="center" style="background:#DCDCDC;" + |Felty's syndrome
!splenomegaly
| align="center" style="background:#F5F5F5;" + |Splenomegaly
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
|-
|-
! rowspan="7" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection-induced
! rowspan="7" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection-induced
! rowspan="3" align="center" style="background:#DCDCDC;" + |Bacterial infections
! rowspan="3" align="center" style="background:#DCDCDC;" + |Bacterial infections
! align="center" style="background:#DCDCDC;" + |Sepsis
! align="center" style="background:#DCDCDC;" + |Sepsis
!Direct bone marrow suppression
| align="center" style="background:#F5F5F5;" + |Direct bone marrow suppression
!+
| align="center" style="background:#F5F5F5;" + |+
!+
| align="center" style="background:#F5F5F5;" + |+
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 690: Line 691:
|-
|-
! align="center" style="background:#DCDCDC;" + |Helicobacter pylori
! align="center" style="background:#DCDCDC;" + |Helicobacter pylori
!Immune thrombocytopenia
| align="center" style="background:#F5F5F5;" + |Immune thrombocytopenia
!
| align="center" style="background:#F5F5F5;" + |
!+
| align="center" style="background:#F5F5F5;" + |+
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 720: Line 721:
|-
|-
! align="center" style="background:#DCDCDC;" + |Tick-borne infection
! align="center" style="background:#DCDCDC;" + |Tick-borne infection
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| +
| align="center" style="background:#F5F5F5;" + |+
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 751: Line 752:
! rowspan="2" align="center" style="background:#DCDCDC;" + |Viral infections
! rowspan="2" align="center" style="background:#DCDCDC;" + |Viral infections
! align="center" style="background:#DCDCDC;" + |HIV
! align="center" style="background:#DCDCDC;" + |HIV
!
| align="Left" style="background:#F5F5F5;" + |
* Direct toxicity to megakaryocytes
* Direct toxicity to megakaryocytes
* An ITP-like condition called primary HIV-associated thrombocytopenia (PHAT)
* An ITP-like condition called primary HIV-associated thrombocytopenia (PHAT)
* Secondary opportunistic infections
* Secondary opportunistic infections
!+
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus
! align="center" style="background:#DCDCDC;" + |Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus
!
| align="center" style="background:#F5F5F5;" + |
!+
| align="center" style="background:#F5F5F5;" + |+
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
|-
|-
! rowspan="2" align="center" style="background:#DCDCDC;" + |Intracellular parasites
! rowspan="2" align="center" style="background:#DCDCDC;" + |Intracellular parasites
! align="center" style="background:#DCDCDC;" + |Malaria
! align="center" style="background:#DCDCDC;" + |Malaria
|
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 845: Line 846:
|-
|-
! align="center" style="background:#DCDCDC;" + |Babesiosis  
! align="center" style="background:#DCDCDC;" + |Babesiosis  
|
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 919: Line 920:
** Phenytoin
** Phenytoin
* Quinine
* Quinine
|Occurrence of drug-dependent, platelet-reactive antibodies
| align="center" style="background:#F5F5F5;" + |Occurrence of drug-dependent, platelet-reactive antibodies
|
| align="center" style="background:#F5F5F5;" + |
| +
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 949: Line 950:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Heparin-induced thrombocytopenia
! colspan="2" align="center" style="background:#DCDCDC;" + |Heparin-induced thrombocytopenia
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| +
| align="center" style="background:#F5F5F5;" + |+
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 979: Line 980:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Cytotoxic chemotherapy
! colspan="2" align="center" style="background:#DCDCDC;" + |Cytotoxic chemotherapy
|
| align="center" style="background:#F5F5F5;" + |
| +
| align="center" style="background:#F5F5F5;" + |+
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,009: Line 1,010:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Radiation therapy
! colspan="2" align="center" style="background:#DCDCDC;" + |Radiation therapy
|Predictable, dose-dependent myelosuppression
| align="center" style="background:#F5F5F5;" + |Predictable, dose-dependent myelosuppression
| +
| align="center" style="background:#F5F5F5;" + |+
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,040: Line 1,041:
! align="center" style="background:#DCDCDC;" + |OTC agents
! align="center" style="background:#DCDCDC;" + |OTC agents
! align="center" style="background:#DCDCDC;" + |Quinine-containing beverages
! align="center" style="background:#DCDCDC;" + |Quinine-containing beverages
|
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,071: Line 1,072:
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |GI
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |GI
! colspan="2" align="center" style="background:#DCDCDC;" + |Chronic liver disease
! colspan="2" align="center" style="background:#DCDCDC;" + |Chronic liver disease
|
| align="center" style="background:#F5F5F5;" + |
| +
| align="center" style="background:#F5F5F5;" + |+
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |Mild
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,101: Line 1,102:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Portal hypertension
! colspan="2" align="center" style="background:#DCDCDC;" + |Portal hypertension
|
|
|
|
|
|
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 1,164: Line 1,165:
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Vascular  
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Vascular  
! colspan="2" align="center" style="background:#DCDCDC;" + |Giant capillary hemangioma  
! colspan="2" align="center" style="background:#DCDCDC;" + |Giant capillary hemangioma  
!platelet destruction  
| align="center" style="background:#F5F5F5;" + |Platelet destruction  
!
| align="center" style="background:#F5F5F5;" + |
!+
| align="center" style="background:#F5F5F5;" + |+
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Aortic aneurysm  
! colspan="2" align="center" style="background:#DCDCDC;" + |Aortic aneurysm  
!platelet destruction  
| align="center" style="background:#F5F5F5;" + |Platelet destruction  
!
| align="center" style="background:#F5F5F5;" + |
!+
| align="center" style="background:#F5F5F5;" + |+
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Cardiopulmonary bypass
! colspan="2" align="center" style="background:#DCDCDC;" + |Cardiopulmonary bypass
!platelet destruction  
| align="center" style="background:#F5F5F5;" + |Platelet destruction  
!
| align="center" style="background:#F5F5F5;" + |
!+
| align="center" style="background:#F5F5F5;" + |+
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
|-
|-
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! colspan="2" align="center" style="background:#DCDCDC;" + |Alcohol
! colspan="2" align="center" style="background:#DCDCDC;" + |Alcohol
!
| align="center" style="background:#F5F5F5;" + |
!+
| align="center" style="background:#F5F5F5;" + |+
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Post-transfusion purpura
! colspan="2" align="center" style="background:#DCDCDC;" + |Post-transfusion purpura
!immune-mediated platelet destruction
| align="center" style="background:#F5F5F5;" + |Immune mediated platelet destruction  
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |+
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" + |Gestational thrombocytopenia
! colspan="2" align="center" style="background:#DCDCDC;" + |Gestational thrombocytopenia
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!+
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
!
| align="center" style="background:#F5F5F5;" + |
|}
|}
<references />
<references />

Revision as of 22:30, 14 August 2018

Thrombocytopenia Differential Diagnosis

Differentiating the diseases that can cause thrombocytopenia:

Category Condition Mechanism Mechanism Inherited Acquried Clinical manifestations Para−clinical findings Gold standard Associated findings
Age range History Symptoms Signs
Lab Findings Imaging
Severity Fever Rash Bleeding BP Splenomegaly Jaundice Other CBC PBS Bone marrow exam PT PTT BT UA
Decreased platelet production Platelet destruction in bloodstream Platelet destruction in spleen/liver Plt HB WBC
Hematology Bone marrow disorders Myelodysplastic syndromes +
Aplastic anemia +
Acute leukemia +
Paroxysmal nocturnal hemoglobinuria (PNH) +
Thrombotic microangiopathy (TMA) Thrombotic thrombocytopenic purpura (TTP) +
Hemolytic uremic syndrome (HUS) +
DIC +
Congenital platelet disorders MYH-9 related disorders
Bernard-Soulier syndrome
Gray platelet syndrome
Wiskott-Aldrich syndrome
Thrombocytopenia with absent radius (TAR) syndrome
Alport syndrome
Von Willebrand disease
Nutrient deficiencies Folate, vitamin B12, copper +
Category Condition Mechanism Decreased platelet production Platelet destruction in bloodstream Platelet destruction in spleen/liver Inherited Acquried Age range History Severity Fever Rash Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam PT PTT BT UA Imaging Gold standard Associated findings
Rheumatologic/autoimmune disorders Immune thrombocytopenia Antibody-mediated platelet destruction +
Systemic lupus erythematosus (SLE)
Antiphospholipid syndrome (APS) Autoantibody-mediated syndrome
Felty's syndrome Splenomegaly
Infection-induced Bacterial infections Sepsis Direct bone marrow suppression + +
Helicobacter pylori Immune thrombocytopenia +
Tick-borne infection +
Viral infections HIV
  • Direct toxicity to megakaryocytes
  • An ITP-like condition called primary HIV-associated thrombocytopenia (PHAT)
  • Secondary opportunistic infections
Other viruses such as rubella, mumps, varicella, parvovirus, hepatitis C, & Epstein-Barr virus +
Intracellular parasites Malaria
Babesiosis
Category Condition Mechanism Decreased platelet production Platelet destruction in bloodstream Platelet destruction in spleen/liver Inherited Acquried Age range History Severity Fever Rash Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam PT PTT BT UA Imaging Gold standard Associated findings
Medication/toxicity Drug-induced immune thrombocytopenia
  • Antibiotics
    • Sulfonamides
    • Ampicillin
    • Piperacillin
    • Vancomycin
    • Rifampin
  • Older antiepileptic agents
    • carbamazepine
    • Phenytoin
  • Quinine
Occurrence of drug-dependent, platelet-reactive antibodies
Heparin-induced thrombocytopenia +
Cytotoxic chemotherapy +
Radiation therapy Predictable, dose-dependent myelosuppression +
OTC agents Quinine-containing beverages
GI Chronic liver disease +
Portal hypertension
Category Condition Mechanism Decreased platelet production Platelet destruction in bloodstream Platelet destruction in spleen/liver Inherited Acquried Age range History Severity Fever Rash Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam PT PTT BT UA Imaging Gold standard Associated findings
Vascular Giant capillary hemangioma Platelet destruction +
Aortic aneurysm Platelet destruction +
Cardiopulmonary bypass Platelet destruction +
Other Alcohol +
Post-transfusion purpura Immune mediated platelet destruction +
Gestational thrombocytopenia